RLMD
What one share of Relmada Therapeutics holds
Pharmaceutical Preparations
Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology company. We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025.
Relmada Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.85 |
|---|---|
| Cash and investments | $0.11 |
| Book value | $1.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$2.08 | $0.02 | −$2.16 | — | $0.47 |
| 2018 | — | −$2.86 | $0.00 | −$1.92 | — | −$1.76 |
| 2019 | — | −$2.74 | — | −$1.66 | — | $0.78 |
| 2019 | — | −$1.62 | $9.18 | −$10.49 | — | $8.00 |
| 2020 | — | −$3.81 | $11.67 | −$13.46 | — | $6.46 |
| 2021 | — | −$7.16 | — | −$5.23 | — | $7.51 |
| 2022 | — | −$5.30 | — | −$3.50 | — | $4.67 |
| 2023 | — | −$3.28 | — | −$1.72 | — | $2.84 |
| 2024 | — | −$2.65 | — | −$1.72 | — | $1.18 |
| 2025 | — | −$1.45 | — | −$1.16 | — | $1.18 |